News
Martin Kerschensteiner receives ERC Advanced Grant
Martin Kerschensteiner is elected as the new BMC Speaker
June 2026: The European Research Council will provide substantial funding for the research proposal “TACO – Targeting myeloid cell states, actions and interactions in neuroinflammation”. With this project Martin Kerschensteiner and his team aim to leverage advanced CRISPR screening approaches to better understand and target the role of ...
February 2026: Ten years after its founding, the Biomedical Center of the LMU Munich has seen its first change in leadership following the retirement of Peter Becker. Martin Kerschensteiner who previously served as deputy speaker will take over as BMC speaker and Antje Grosche and Michael Kiebler are the new...
Publications
In vivo CRISPR screen reveals regulation of macrophage states in neuroinflammation
SV2A-PET imaging uncovers cortical synapse loss in multiple sclerosis
February 2026 – Here the Kerschensteiner lab developed a new CRISPR-based in vivo screening platform that reveals how cytokines orchestrate macrophage behavior in multiple sclerosis. By editing progenitor cells before transplantation, they mapped how key immune signals—like IFN-γ,TNF...
October 2025 – Gray matter damage and cortical lesions drive progression in people with multiple sclerosis (PwMS). In a new study, the Kerschensteiner lab collaborated with our clinical team and the group of Matthias Brendel at the Department of Nuclear Medicine to show that positron emission...